Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05027477 | A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer(CAPTAIN) | active not recruiting | N/A | 201 | Profound Medical Inc.OTHER | 3 | Aug 17, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03776630 | Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors(GYNO-MIR) | active not recruiting | N/A | 363 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06632951 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)(LIVIGNO-3) | active not recruiting | Phase 2 | 150 | AbbVieINDUSTRY | 8 | Aug 11, 2025 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06197802 | Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women | active not recruiting | — | 392 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06243666 | Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls | active not recruiting | — | 2,188 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer(PrTK03) | active not recruiting | Phase 3 | 711 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | active not recruiting | Phase 2 | 187 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04181203 | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy(CARLHA-2) | active not recruiting | Phase 3 | 490 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05269550 | PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER)(ARGOS/CLIMBER) | active not recruiting | N/A | 50 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 | 67 | MedImmune LLCINDUSTRY | 4 | Jul 25, 2025 | clinicaltrials |
| NCT05056402 | An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | active not recruiting | Phase 3 | 1,382 | Xiamen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07074795 | Use of Nitrous Oxide During Office Hysteroscopy | active not recruiting | N/A | 400 | Maaynei Hayesha Medical CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07063758 | A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma | active not recruiting | — | 200 | National Taiwan University Clinical Trial CenterOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04404894 | Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing | active not recruiting | — | 500 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07060248 | A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness. | active not recruiting | — | 700 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Dong WenOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07048613 | Comparative Study of MRI and TU in Identifying Clinically Significant Prostate Cancer Among Ethnic Groups | active not recruiting | — | 120 | Superior UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05887245 | Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy | active not recruiting | — | 200 | Centre of Postgraduate Medical EducationOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis(MEGACEP) | active not recruiting | Phase 2 | 37 | UNICANCEROTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT04105920 | Evaluation of the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies(HYALEREC) | active not recruiting | N/A | 162 | Hospices Civils de LyonOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05996783 | Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial(ScreenUrSelf) | active not recruiting | N/A | 48,000 | Universiteit AntwerpenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT01342367 | Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | active not recruiting | N/A | 74 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05219318 | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI) | active not recruiting | Phase 3 | 22 | University Hospital, BordeauxOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03564275 | Proton Boost in Prostate Cancer | active not recruiting | N/A | 10 | University of CincinnatiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04120805 | Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy | active not recruiting | N/A | 178 | University of ChicagoOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT01783145 | Shared Care Follow-up After Chemotherapy for Testicular Cancer(SCFU-TC) | active not recruiting | — | 163 | University Medical Center GroningenOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02572934 | Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)(STANDBY) | active not recruiting | — | 281 | University Medical Center GroningenOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03392181 | PET/MRI for the Staging of Newly Diagnosed Prostate Cancer | active not recruiting | Early Phase 1 | 48 | Northwestern UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06985004 | Predicting Operational Difficulties and Outcomes of RARP Based on Preoperative Assessment - Introducing the PIODO Questionnaire | active not recruiting | — | 288 | Pomeranian Medical University SzczecinOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT05592639 | VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer(VELRAD) | active not recruiting | N/A | 50 | University College, LondonOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04848909 | Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy(PLUTO-MPC) | active not recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer(LuPARP) | active not recruiting | Phase 1 | 70 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2025source: clinicaltrials